AQST - Aquestive receives conditional FDA approval for proprietary name Anaphylm for lead candidate AQST-109
2023-04-20 10:42:57 ET
- Aquestive Therapeutics ( NASDAQ: AQST ) disclosed that the FDA has conditionally sanctioned Anaphylm as the proposed brand name for AQST-109, which is used to treat severe allergic reactions, particularly anaphylaxis.
- The proprietary name Anaphylm was developed after an extensive process involving external branding experts as well as patient feedback, the company said.
- Press Release
For further details see:
Aquestive receives conditional FDA approval for proprietary name Anaphylm for lead candidate AQST-109